← Leaderboards
Michael David Alpert
Emmune, Inc
$15,939,345
Attributed
$22,696,968
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,696,968 · 12
By mechanism
R44$18,663,414 · 7
U19$2,292,326 · 1
R56$917,294 · 1
R43$823,934 · 3
Top collaborators
- Michael R. Farzan7 shared
- Mia L Huang4 shared
- Charles Corbin Bailey2 shared
- Hyeryun None Choe2 shared
- Mauricio De Aguiar Martins1 shared
- Brian D Quinlan1 shared
- Guocai Zhong1 shared
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Dennis R. Burton · Scripps Research Institute$328,455,703
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
Research focus
Neutralizing AntibodyAntibodiesPreventPharmaceutical PreparationsViralProteinsEngineeringDoseMacacaImmune ResponseImmunogenicMediatingCcr5 GeneMacaca MulattaPeptidomimeticsAdeno-Associated Viral VectorCostReceptorSimian Human Immunodeficiency VirusMuscleVariantInfectionHiv ReceptorsAntibody Response
Grant awards (33)
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$1,000,000
R44 · FY2025 · AI · contact PI
Process development for manufacturing eCD4-Ig$999,997
R44 · FY2025 · AI · contact PI
Non-viral gene therapy with eCD4-Ig$917,294
R56 · FY2025 · AI
IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic$300,000
R43 · FY2025 · AI · contact PI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$1,000,000
R44 · FY2024 · AI · contact PI
Glycoengineering eCD4-Ig$974,661
R44 · FY2024 · AI · contact PI
Project 3:Optimal use of ART in establishing functional cures$314,843
U19 · FY2024 · AI · contact PI
Engineering AAV capsids for enhanced transduction of skeletal muscle$1,012,172
R44 · FY2023 · TR · contact PI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$1,000,000
R44 · FY2023 · AI · contact PI
Glycoengineering eCD4-Ig$1,000,000
R44 · FY2023 · AI · contact PI
Project 3:Optimal use of ART in establishing functional cures$334,093
U19 · FY2023 · AI · contact PI
Process development for manufacturing eCD4-Ig$299,998
R44 · FY2023 · AI · contact PI
Engineering AAV capsids for enhanced transduction of skeletal muscle$1,012,172
R44 · FY2022 · TR · contact PI
Glycoengineering eCD4-Ig$974,663
R44 · FY2022 · AI · contact PI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$907,386
R44 · FY2022 · AI · contact PI
SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites$300,000
R44 · FY2022 · AI · contact PI
Project 3:Optimal use of ART in establishing functional cures$230,699
U19 · FY2022 · AI · contact PI
Project 3:Optimal use of ART in establishing functional cures$1,041,441
U19 · FY2021 · AI · contact PI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$870,946
R44 · FY2021 · AI · contact PI
Glycoengineering eCD4-Ig$300,000
R44 · FY2021 · AI · contact PI
Development of AAV vectors for long-term expression of eCD4-Ig$999,443
R44 · FY2020 · AI · contact PI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$886,103
R44 · FY2020 · AI
Project 3:Optimal use of ART in establishing functional cures$371,250
U19 · FY2020 · AI · contact PI
Engineering AAV capsids for enhanced transduction of skeletal muscle$292,899
R44 · FY2020 · TR · contact PI
Development of AAV vectors for long-term expression of eCD4-Ig$999,675
R44 · FY2019 · AI · contact PI
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig$300,000
R44 · FY2019 · AI
Development of AAV vectors for long-term expression of eCD4-Ig$999,959
R44 · FY2018 · AI · contact PI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$998,663
R44 · FY2018 · AI · contact PI
Cpf1-mediated inactivation of an AAV transgene$300,000
R43 · FY2018 · AI · contact PI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$937,245
R44 · FY2017 · AI · contact PI
Development of AAV vectors for long-term expression of eCD4-Ig$299,239
R44 · FY2017 · AI · contact PI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$298,193
R44 · FY2016 · AI · contact PI
Development of a synthetic antibody based on the HIV receptor and co-receptor that is optimized for highly efficient killing of HIV-infected cells by ADCC$223,934
R43 · FY2015 · AI · contact PI